Commonwealth Equity Services LLC lifted its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 19.4% in the first quarter, according to its most recent filing with the SEC. The fund owned 23,448 shares of the medical research company’s stock after acquiring an additional 3,811 shares during the period. Commonwealth Equity Services LLC’s holdings in Charles River Laboratories International were worth $4,732,000 as of its most recent SEC filing.
Other hedge funds also recently made changes to their positions in the company. Mitsubishi UFJ Trust & Banking Corp lifted its holdings in shares of Charles River Laboratories International by 0.3% during the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 158,988 shares of the medical research company’s stock worth $32,087,000 after acquiring an additional 512 shares during the last quarter. CIBC Asset Management Inc lifted its holdings in shares of Charles River Laboratories International by 6.1% during the 4th quarter. CIBC Asset Management Inc now owns 7,127 shares of the medical research company’s stock worth $1,553,000 after acquiring an additional 412 shares during the last quarter. Belpointe Asset Management LLC lifted its holdings in shares of Charles River Laboratories International by 8.7% during the 4th quarter. Belpointe Asset Management LLC now owns 1,178 shares of the medical research company’s stock worth $257,000 after acquiring an additional 94 shares during the last quarter. Deutsche Bank AG lifted its holdings in shares of Charles River Laboratories International by 1.7% during the 4th quarter. Deutsche Bank AG now owns 188,646 shares of the medical research company’s stock worth $41,106,000 after acquiring an additional 3,223 shares during the last quarter. Finally, Congress Wealth Management LLC DE lifted its stake in Charles River Laboratories International by 4.6% in the first quarter. Congress Wealth Management LLC DE now owns 53,330 shares of the medical research company’s stock worth $10,763,000 after purchasing an additional 2,358 shares during the last quarter. 98.91% of the stock is owned by institutional investors.
Charles River Laboratories International Price Performance
Shares of CRL opened at $209.62 on Friday. The stock has a market cap of $10.75 billion, a PE ratio of 22.23, a price-to-earnings-growth ratio of 1.78 and a beta of 1.33. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.21 and a current ratio of 1.49. Charles River Laboratories International, Inc. has a fifty-two week low of $181.22 and a fifty-two week high of $262.00. The firm’s 50-day simple moving average is $206.90 and its two-hundred day simple moving average is $205.33.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on CRL shares. Wells Fargo & Company lowered their price target on shares of Charles River Laboratories International from $290.00 to $280.00 in a research note on Friday, May 12th. TheStreet downgraded shares of Charles River Laboratories International from a “b-” rating to a “c” rating in a research note on Thursday, May 11th. JPMorgan Chase & Co. boosted their price target on shares of Charles River Laboratories International from $225.00 to $250.00 and gave the stock an “overweight” rating in a research note on Thursday, August 10th. Credit Suisse Group lowered their price target on shares of Charles River Laboratories International from $260.00 to $255.00 in a research note on Friday, May 12th. Finally, StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Saturday. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and an average target price of $247.80.
View Our Latest Research Report on Charles River Laboratories International
Insider Transactions at Charles River Laboratories International
In related news, Director Richard F. Wallman acquired 1,000 shares of the stock in a transaction that occurred on Thursday, August 24th. The shares were bought at an average price of $198.79 per share, for a total transaction of $198,790.00. Following the completion of the transaction, the director now directly owns 1,000 shares in the company, valued at $198,790. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 700 shares of the stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $216.52, for a total value of $151,564.00. Following the transaction, the executive vice president now directly owns 24,983 shares in the company, valued at $5,409,319.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Richard F. Wallman acquired 1,000 shares of Charles River Laboratories International stock in a transaction dated Thursday, August 24th. The stock was purchased at an average cost of $198.79 per share, with a total value of $198,790.00. Following the completion of the purchase, the director now owns 1,000 shares of the company’s stock, valued at $198,790. The disclosure for this purchase can be found here. Over the last 90 days, insiders have sold 7,934 shares of company stock worth $1,722,048. Corporate insiders own 1.30% of the company’s stock.
Charles River Laboratories International Company Profile
Charles River Laboratories International, Inc, a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).
Featured Stories
- Five stocks we like better than Charles River Laboratories International
- What Are the U.K. Market Holidays? How to Invest and Trade
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- Where to Find Earnings Call Transcripts
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
- Stock Market Upgrades: What Are They?
- 5 Critical Takeaways From MongoDB’s Q2 Results for AI Investors
Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL – Free Report).
Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.
